

Media Release: Australia | 2 September 2026

New strategic partnership set to boost national health security capabilities

Biointellect and Health Security Systems Australia (HSSA), a division of DMTC Limited, have announced a new strategic partnership designed to help support Australia's health security capabilities.

The announcement comes as Australia faces increasingly complex, globally interconnected health security threats. These include emerging infectious diseases, future pandemics, rising antimicrobial resistance, and biological hazards.

Australia's ability to anticipate, detect and respond rapidly to these threats hinges on ensuring research, industry, government and end-user capabilities are connected and ready to turn innovation into practical solutions.

The partnership will boost Australia's resilience and preparedness for current and emerging health threats through enhanced cooperation and coordination.

It will explore opportunities to support infectious disease innovations with local and global health security impact, and technologies with dual civilian and military applications.

Clearer, more efficient product pathways - from research and development to commercialisation and end-user adoption - will be a key focus.

HSSA brings extensive experience in driving research and development, and capability-building to address national health and security threats. Biointellect's expertise lies in life science innovation commercialisation, regulatory strategy, clinical trials and product development. In partnership, they will support a connected health innovation ecosystem and help Australian innovators speed up the translation of research into practice.

The agreement provides a framework to jointly pursue opportunities that align with shared goals of strengthening Australia's capability in health security, infectious disease preparedness and technology development. Examples of innovative health technologies include vaccines, immunotherapeutics, diagnostics and platform technologies.

Announcement of the partnership coincides with the Australian Vaccine Value Chain Conference (AVVCC26), being held in Sydney this week, where leaders from government, industry, research and healthcare are convening to strengthen Australia's vaccine and infectious disease innovation ecosystem. The timing reflects the growing importance of cross-sector collaboration in advancing Australia's health innovation and security capabilities.

Leah Goodman, Chief Executive Officer, Biointellect:

"Health security challenges increasingly require cross-sector collaboration and the ability to draw on expertise from across Australia's innovation ecosystem."

"This partnership brings together complementary expertise and networks that can help speed up the development and delivery of technologies that boost Australia's health security and sovereign capability."

Harry Baxter, Health Security Systems Australia and Government Relations Head, DMTC:

"Global health security is an urgent challenge, and two recent severe bacterial outbreaks in Northern Australia show we cannot be complacent. Australia's ability to respond requires collaboration across government, research, industry and the broader innovation ecosystem. This agreement enables HSSA and Biointelect to explore opportunities to combine our capabilities for national benefit."

"We are particularly excited about the opportunity to strengthen pathways between research, capability development, commercialisation and end-user needs, helping ensure promising Australian innovations have the greatest possible opportunity to create real-world impact."

Danielle Shand, General Manager, Biointelect Venturer:

"Biointelect Venturer is helping bridge the gap between scientific discovery and successful commercial outcomes in infectious disease innovation."

By partnering with HSSA, we can help connect innovators with the broader networks, expertise and pathways needed to accelerate the translation of innovations to strengthen both national and global health security."

Building Australia's Health Security Future**About Biointelect**

Biointelect Venturer leverages the breadth of Biointelect's full-service CRO and commercialisation capabilities which has helped hundreds of emerging biotech and medtech companies translate innovation into commercial success. Drawing on expertise spanning research and development, clinical strategy and execution, regulatory affairs, market access, health economics, reimbursement and commercialisation planning, Biointelect provides both the technical delivery and strategic guidance required to progress products from concept and clinical development through to investment readiness, market adoption and patient impact.

About Biointelect Venturer

Biointelect Venturer is Australia's national incubator for infectious disease innovation, helping promising Australian scientific innovators accelerate their path from discovery to impact. Funded by the Australian Government's Medical Research Future Fund (MRFF) through the 2024 BioMedTech Incubator grant opportunity, Biointelect Venturer combines catalytic non-dilutive funding with commercialisation expertise, strategic guidance, networks and tailored support to progress early-stage innovations towards commercial and investment readiness. Managed and operated by Biointelect, the incubator builds on Biointelect's deep expertise and success in supporting early-stage biotech and medtech commercialisation.

About Health Security Systems Australia (HSSA)

Health Security Systems Australia, a division of DMTC Limited, leads collaborative capability uplift and research and development initiatives designed to mitigate threats posed by chemical, biological, radiological and nuclear hazards, including infectious diseases and pandemics, for both Defence and civilian populations. HSSA works with partners across government, industry, academia and Defence to strengthen Australia's health security capabilities and resilience.

Media Contacts

Biointellect Venturer
Andrew Bowskill
Partnership and Stakeholder Lead
M: +61 (0) 423 644 044
E: abowskill@biointellect.com

HSSA
Emily Kibble
Program Leader – Strategic Advisory
M: +61 (0) 406 857 321
E: emily.kibble@dmtd.com.au